4 European Projects Found
Searched on 125080 European Projects
FINISHED
A common European approach to the regulatory testing of nanomaterials (NANOREG)
Start date: Mar 1, 2013, End date: Feb 28, 2017,
The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issues. While toxicity data is continuously becoming available, the relevance to regulators is often unclear or unproven. The shrinking time to market of new MNM drives the need for urgent action by regulators. NANoREG is the first FP7 project to deliver the answe ...
Read Project
73
Partners Participants
FINISHED
Combined Highly Active Anti-retroviral Microbicides (CHAARM)
Start date: Jan 1, 2010, End date: Jun 30, 2015,
This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of r ...
Read Project
34
Partners Participants
FINISHED
Integration of Chikungunya research (ICRES)
Start date: Dec 1, 2010, End date: Nov 30, 2014,
Since 2005 Chikungunya fever has affected millions of people producing a high fever and a debilitating arthralgia which can persist for months and progress to chronic arthritis. Chikungunya virus has been associated with periodic outbreaks of human disease and is spread by mosquitoes. The current epidemic rose to prominence in 2005/6 following infection of >250,000 people on La Réunion. The virus ...
Read Project
15
Partners Participants
FINISHED
EUROpean consortium on NEUTralising antibodies using gp41 (EURONEUT-41)
Start date: Jan 1, 2008, End date: Mar 31, 2014,
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed ...
Read Project
